229 related articles for article (PubMed ID: 28721822)
1. Opioid Antagonists for Pharmacological Treatment of Gambling Disorder: Are they Relevant?
Victorri-Vigneau C; Spiers A; Caillet P; Bruneau M; Ignace-Consortium ; Challet-Bouju G; Grall-Bronnec M
Curr Neuropharmacol; 2018; 16(10):1418-1432. PubMed ID: 28721822
[TBL] [Abstract][Full Text] [Related]
2. Current pharmacotherapy for gambling disorder: a systematic review.
Kraus SW; Etuk R; Potenza MN
Expert Opin Pharmacother; 2020 Feb; 21(3):287-296. PubMed ID: 31928246
[No Abstract] [Full Text] [Related]
3. Treatment of cocaine craving with as-needed nalmefene, a partial κ opioid receptor agonist: first clinical experience.
Grosshans M; Mutschler J; Kiefer F
Int Clin Psychopharmacol; 2015 Jul; 30(4):237-8. PubMed ID: 25647453
[TBL] [Abstract][Full Text] [Related]
4. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling.
Grant JE; Potenza MN; Hollander E; Cunningham-Williams R; Nurminen T; Smits G; Kallio A
Am J Psychiatry; 2006 Feb; 163(2):303-12. PubMed ID: 16449486
[TBL] [Abstract][Full Text] [Related]
5. Opioid receptor antagonists in the treatment of pathological gambling.
Coppola M; Mondola R
J Opioid Manag; 2017; 13(4):205-206. PubMed ID: 28983886
[No Abstract] [Full Text] [Related]
6. Pharmacological management of gambling disorder: an update of the literature.
Mestre-Bach G; Potenza MN
Expert Rev Neurother; 2024 Apr; 24(4):391-407. PubMed ID: 38357896
[TBL] [Abstract][Full Text] [Related]
7. The μ-opioid receptor and treatment response to naltrexone.
Thorsell A
Alcohol Alcohol; 2013; 48(4):402-8. PubMed ID: 23543091
[TBL] [Abstract][Full Text] [Related]
8. Opioid antagonists in broadly defined behavioral addictions: a narrative review.
Piquet-Pessôa M; Fontenelle LF
Expert Opin Pharmacother; 2016; 17(6):835-44. PubMed ID: 26798982
[TBL] [Abstract][Full Text] [Related]
9. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?
Bart G; Schluger JH; Borg L; Ho A; Bidlack JM; Kreek MJ
Neuropsychopharmacology; 2005 Dec; 30(12):2254-62. PubMed ID: 15988468
[TBL] [Abstract][Full Text] [Related]
10. Naltrexone: A Pan-Addiction Treatment?
Aboujaoude E; Salame WO
CNS Drugs; 2016 Aug; 30(8):719-33. PubMed ID: 27401883
[TBL] [Abstract][Full Text] [Related]
11. Pathological gambling: focusing on the addiction, not the activity.
Tamminga CA; Nestler EJ
Am J Psychiatry; 2006 Feb; 163(2):180-1. PubMed ID: 16449466
[No Abstract] [Full Text] [Related]
12. A Randomised, Double-Blind, Placebo-Controlled Trial of As-Needed Naltrexone in the Treatment of Pathological Gambling.
Kovanen L; Basnet S; Castrén S; Pankakoski M; Saarikoski ST; Partonen T; Alho H; Lahti T
Eur Addict Res; 2016; 22(2):70-9. PubMed ID: 26339899
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological treatments in pathological gambling.
Grant JE; Odlaug BL; Schreiber LR
Br J Clin Pharmacol; 2014 Feb; 77(2):375-81. PubMed ID: 22979951
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence.
Walker BM; Koob GF
Neuropsychopharmacology; 2008 Feb; 33(3):643-52. PubMed ID: 17473837
[TBL] [Abstract][Full Text] [Related]
15. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
Baker AK; Meert TF
J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
[TBL] [Abstract][Full Text] [Related]
16. The current clinical knowledge on the treatment of gambling disorder: A summary.
Hloch K; Mladěnka P; Doseděl M; Adriani W; Zoratto F
Synapse; 2017 Aug; 71(8):. PubMed ID: 28420033
[TBL] [Abstract][Full Text] [Related]
17. Opioid Receptor Antagonists in the Treatment of Alcoholism.
Serecigni JG
Adicciones; 2015 Sep; 27(3):214-30. PubMed ID: 26437315
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the Impact of Naltrexone on the Rat Gambling Task to Test Its Predictive Validity for Gambling Disorder.
Di Ciano P; Le Foll B
PLoS One; 2016; 11(5):e0155604. PubMed ID: 27191857
[TBL] [Abstract][Full Text] [Related]
19. Naltrexone in the Treatment of Broadly Defined Behavioral Addictions: A Review and Meta-Analysis of Randomized Controlled Trials.
Mouaffak F; Leite C; Hamzaoui S; Benyamina A; Laqueille X; Kebir O
Eur Addict Res; 2017; 23(4):204-210. PubMed ID: 28877518
[TBL] [Abstract][Full Text] [Related]
20. Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential.
Soyka M
Expert Opin Pharmacother; 2016; 17(4):619-26. PubMed ID: 26810044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
